Question 1

What is Supernus Pharmaceuticals's deferred tax assets and other non-current assets?

Accepted Answer

Supernus Pharmaceuticals (SUPN) reported deferred tax assets and other non-current assets of $56.45M in Q1 2026.

Question 2

How has Supernus Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?

Accepted Answer

Supernus Pharmaceuticals's deferred tax assets and other non-current assets increased by 93.2% year-over-year, from $29.22M to $56.45M.

Question 3

What is the long-term trend for Supernus Pharmaceuticals's deferred tax assets and other non-current assets?

Accepted Answer

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 8.1% compound annual growth rate (CAGR), from $43.25M to $63.8M.

Line item	March 31, 2026	December 31, 2025
Intangible assets, net	549,712	569,456
Goodwill	120,668	124,882
Deferred income tax assets, net	30,820	38,351
Other assets	56,453	63,796
Total assets	$1,500,725	$1,452,648
Liabilities and stockholders' equity
Current liabilities
Accounts payable and accrued liabilities	$101,244	$107,800

Deferred Tax Assets and Other Non-Current Assets at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Supernus Pharmaceuticals's deferred tax assets and other non-current assets.

Supernus Pharmaceuticals SUPN Deferred Tax Assets and Other Non-Current Assets